Dr. Reddy's Laboratories Ltd.

413 articles with Dr. Reddy's Laboratories Ltd.

• Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

  5/13/2021

  Shenzhen Pregene Biopharma and Dr. Reddy's Laboratories announce a license agreement whereby Dr Reddy's will acquire the exclusive rights in the Republic of India for PRG1801, an anti-BCMA CAR-T cell therapy injection based on single domain antibody technology, from Shenzhen Pregene Biopharma.

• Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

  5/12/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ for injection, 1 g/vial approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

  4/29/2021

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

  4/13/2021

  Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act.

• Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

  4/7/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan® Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market

  2/22/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V

  2/19/2021

  Dr. Reddy’s Laboratories Ltd. announced that it has initiated the process with the Drugs Controller General of India for Emergency Use Authorization of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V.

• Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market

  2/18/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market

  2/17/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market

  2/2/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril® Tablets, USP, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Q3 & 9M FY21 Financial Results

  1/29/2021

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the nine months ended December 31, 2020.

• Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update

  1/27/2021

  Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America

• Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.

• Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

  12/22/2020

  Dr. Reddy’s Laboratories Ltd., Appili Therapeutics and Global Response Aid FZCO announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

• Secondary Listing of Dr. Reddy’s ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)

  12/9/2020

  Dr. Reddy’s Laboratories Ltd. announced the secondary listing of its American Depository Receipts on NSE IFSC Limited under the symbol ’DRREDDY’ on December 9, 2020.

• Dr. Reddy’s to Acquire Select Anti-Allergy Brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan 

  11/28/2020

  Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino, Momat Rino Advance, Momat A, Glenspray and Glenspray Active, along-with rights to the trademarks, dossiers and patents for the territories mentioned.

• Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

  11/9/2020

  Dr. Reddy’s Laboratories Ltd. announced a preclinical data presentation for E7777, its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, being held virtually.

• Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

  10/29/2020

  Dr. Reddy’s Laboratories Ltd., announced its partnership with Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

• Dr. Reddy’s Q2 & H1 FY21 Financial Results

  10/28/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2020.